Literature DB >> 19822293

Dichotomous role of interferon-gamma in allogeneic bone marrow transplant.

Ying Lu1, Edmund K Waller.   

Abstract

Interferon (IFN)-gamma is a pleiotropic cytokine with a central role in innate and adaptive immunity. As a potent pro-inflammatory and antitumor cytokine, IFN-gamma is conventionally thought to be responsible for driving cellular immune response. On the other hand, accumulating evidence suggests that IFN-gamma also has immunosuppressive activity. An important role for IFN-gamma in inhibiting graft-versus-host disease (GVHD) has been demonstrated in murine models, despite IFN-gamma being one of the key factors amplifying T cell activation during the process of acute GVHD (aGVHD), the major complication and cause of post-transplant mortality in allogeneic bone marrow transplantation (BMT). At the same time, IFN-gamma facilitates graft-versus-leukemia (GVL) activity. Dissociation of GVL effects from GVHD has been the ultimate goal of allogeneic BMT in the treatment of hematologic malignancies. This paradoxic role of IFN-gamma makes modulating its activity a promising strategy to maximize GVL while minimizing GVHD and improve clinical outcomes in BMT. In this review, the effects of IFN-gamma on GVHD and GVL are discussed with consideration of the mechanism of IFN-gamma action.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19822293      PMCID: PMC2782586          DOI: 10.1016/j.bbmt.2009.07.015

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  86 in total

1.  IFN-gamma-mediated prevention of graft-versus-host disease: pharmacodynamic studies and influence on proliferative capacity of chimeric spleen cells.

Authors:  H P Brok; J M Vossen; P J Heidt
Journal:  Bone Marrow Transplant       Date:  1998-11       Impact factor: 5.483

2.  Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.

Authors:  O Asai; D L Longo; Z G Tian; R L Hornung; D D Taub; F W Ruscetti; W J Murphy
Journal:  J Clin Invest       Date:  1998-05-01       Impact factor: 14.808

3.  Interleukin-12 preserves the graft-versus-leukemia effect of allogeneic CD8 T cells while inhibiting CD4-dependent graft-versus-host disease in mice.

Authors:  Y G Yang; J J Sergio; D A Pearson; G L Szot; A Shimizu; M Sykes
Journal:  Blood       Date:  1997-12-01       Impact factor: 22.113

4.  Interferon-gamma-mediated prevention of graft-versus-host disease: development of immune competent and allo-tolerant T cells in chimeric mice.

Authors:  H P Brok; J M Vossen; P J Heidt
Journal:  Bone Marrow Transplant       Date:  1997-03       Impact factor: 5.483

5.  IL-2 inhibits early increases in serum gamma interferon levels associated with graft-versus-host-disease.

Authors:  J Szebeni; M G Wang; D A Pearson; G L Szot; M Sykes
Journal:  Transplantation       Date:  1994-12-27       Impact factor: 4.939

Review 6.  The molecular cell biology of interferon-gamma and its receptor.

Authors:  M A Farrar; R D Schreiber
Journal:  Annu Rev Immunol       Date:  1993       Impact factor: 28.527

7.  Cytokine involvement in predicting clinical graft-versus-host disease in allogeneic bone marrow transplant recipients.

Authors:  A M Dickinson; L Sviland; P J Hamilton; P Usher; P Taylor; G Jackson; J Dunn; S J Proctor
Journal:  Bone Marrow Transplant       Date:  1994-01       Impact factor: 5.483

8.  Interleukin-12 inhibits murine graft-versus-host disease.

Authors:  M Sykes; G L Szot; P L Nguyen; D A Pearson
Journal:  Blood       Date:  1995-09-15       Impact factor: 22.113

9.  Interferon-gamma prevents graft-versus-host disease after allogeneic bone marrow transplantation in mice.

Authors:  H P Brok; P J Heidt; P H van der Meide; C Zurcher; J M Vossen
Journal:  J Immunol       Date:  1993-12-01       Impact factor: 5.422

10.  Murine macrophages secrete interferon gamma upon combined stimulation with interleukin (IL)-12 and IL-18: A novel pathway of autocrine macrophage activation.

Authors:  M Munder; M Mallo; K Eichmann; M Modolell
Journal:  J Exp Med       Date:  1998-06-15       Impact factor: 14.307

View more
  26 in total

1.  Multiorgan failure with abnormal receptor metabolism in mice mimicking Samd9/9L syndromes.

Authors:  Akiko Nagamachi; Akinori Kanai; Megumi Nakamura; Hiroshi Okuda; Akihiko Yokoyama; Satoru Shinriki; Hirotaka Matsui; Toshiya Inaba
Journal:  J Clin Invest       Date:  2021-02-15       Impact factor: 14.808

2.  IFNγR signaling mediates alloreactive T-cell trafficking and GVHD.

Authors:  Jaebok Choi; Edward D Ziga; Julie Ritchey; Lynne Collins; Julie L Prior; Matthew L Cooper; David Piwnica-Worms; John F DiPersio
Journal:  Blood       Date:  2012-09-12       Impact factor: 22.113

3.  Absence of Stat1 in donor CD4⁺ T cells promotes the expansion of Tregs and reduces graft-versus-host disease in mice.

Authors:  Huihui Ma; Caisheng Lu; Judith Ziegler; Ailing Liu; Antonia Sepulveda; Hideho Okada; Suzanne Lentzsch; Markus Y Mapara
Journal:  J Clin Invest       Date:  2011-06-13       Impact factor: 14.808

Review 4.  Role of the intestinal mucosa in acute gastrointestinal GVHD.

Authors:  Jonathan U Peled; Alan M Hanash; Robert R Jenq
Journal:  Blood       Date:  2016-11-17       Impact factor: 22.113

5.  IFN-γ and indoleamine 2,3-dioxygenase signaling between donor dendritic cells and T cells regulates graft versus host and graft versus leukemia activity.

Authors:  Ying Lu; Cynthia R Giver; Akshay Sharma; Jian Ming Li; Katarzyna A Darlak; Lauren M Owens; John D Roback; Jacques Galipeau; Edmund K Waller
Journal:  Blood       Date:  2011-11-30       Impact factor: 22.113

6.  Protective role of T-bet and Th1 cytokines in pulmonary graft-versus-host disease and peribronchiolar fibrosis.

Authors:  Kymberly M Gowdy; Julia L Nugent; Tereza Martinu; Erin Potts; Laurie D Snyder; W Michael Foster; Scott M Palmer
Journal:  Am J Respir Cell Mol Biol       Date:  2011-09-29       Impact factor: 6.914

7.  Chitinase 3-Like-1-Deficient Splenocytes Deteriorated the Pathogenesis of Acute Graft-Versus-Host Disease via Regulating Differentiation of Tfh Cells.

Authors:  Zengyao Li; Hao Lu; Jian Gu; Jing Liu; Qin Zhu; Yunjie Lu; Xuehao Wang
Journal:  Inflammation       Date:  2017-10       Impact factor: 4.092

8.  Rituximab-based treatments followed by adoptive cellular immunotherapy for biopsy-proven EBV-associated post-transplant lymphoproliferative disease in recipients of allogeneic hematopoietic stem cell transplantation.

Authors:  Xinmiao Jiang; Lanping Xu; Yu Zhang; Fen Huang; Daihong Liu; Jin Sun; Chaoyang Song; Xinquan Liang; Zhiping Fan; Hongsheng Zhou; Min Dai; Can Liu; Qianli Jiang; Na Xu; Li Xuan; Meiqing Wu; Xiaojun Huang; Qifa Liu
Journal:  Oncoimmunology       Date:  2016-03-10       Impact factor: 8.110

9.  Human mesenchymal stromal cells from adult and neonatal sources: a comparative in vitro analysis of their immunosuppressive properties against T cells.

Authors:  Marta E Castro-Manrreza; Hector Mayani; Alberto Monroy-García; Eugenia Flores-Figueroa; Karina Chávez-Rueda; Victoria Legorreta-Haquet; Edelmiro Santiago-Osorio; Juan José Montesinos
Journal:  Stem Cells Dev       Date:  2014-02-24       Impact factor: 3.272

10.  PRMT5 regulates T cell interferon response and is a target for acute graft-versus-host disease.

Authors:  Katiri J Snyder; Nina C Zitzer; Yandi Gao; Hannah K Choe; Natalie E Sell; Lotus Neidemire-Colley; Anora Ignaci; Charuta Kale; Raymond D Devine; Maria G Abad; Maciej Pietrzak; Min Wang; Hong Lin; Yang W Zhang; Gregory K Behbehani; Jane E Jackman; Ramiro Garzon; Kris Vaddi; Robert A Baiocchi; Parvathi Ranganathan
Journal:  JCI Insight       Date:  2020-04-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.